We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Infectious Disease IVD Sector Unaffected by Vaccine Development

By LabMedica International staff writers
Posted on 23 Dec 2013
A variety of factors will boost the infectious disease IVD market, even if vaccines are developed and widely distributed. More...


Shara Rosen, an analyst at the medical market research company, Kalorama Information (New York, NY, USA) and the author of a new report on the world market for infectious disease tests stated, ‘‘[....] in light of the recent reemergence of tuberculosis, measles, and malaria; and the persistence of polio, it is unrealistic to think that a disease could be totally eliminated around the world at the same time."

Vaccines have been successful in preventing disease, but Kalorama Information believes that does not mean they will upset the market for products to test for those diseases. The healthcare market research publisher says a variety of factors will boost the infectious disease IVD market, even if vaccines are developed and widely distributed. The world market for infectious disease tests is estimated at USD 14.5 billion in 2012, and with 5% Compound Annual Growth Rate (CAGR), will reach USD18.3 billion in 2017, according to their latest report.

In addition, pathogens constantly change their genetic make-up, which challenges the development of vaccines against infectious diseases. This genetic flexibility allows many infectious agents to mutate or evolve into more deadly strains against which humans have little or no resistance: the Human Immunodeficiency Virus (HIV) and influenza viruses, for example, constantly mutate and recombine to find their way through the host defense mechanisms. Finally, the vaccine market may not be strong enough to encourage enough entrants for all the possible infectious diseases. Even existing vaccine markets sometimes fail.

The flu epidemic scare of 2009 resulted in a shortage of flu vaccines, the industry prepared to avoid this in the future. However, things did not quite work out for them. In 2012, companies produced about 145 million doses and only about 129 million were distributed. In 2011, companies lost even more on the flu vaccine because it was such a light flu season and fewer people decided to get the shot.

Kalorama Information is a division of MarketResearch.com; it supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare; as well as a full range of custom research services.

Related Links:

Kalorama Information



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
New
Gel Cards
DG Gel Cards
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.